CN110840966A - 一种用于解酒的组合物及包含其的咀嚼片 - Google Patents
一种用于解酒的组合物及包含其的咀嚼片 Download PDFInfo
- Publication number
- CN110840966A CN110840966A CN201911298679.6A CN201911298679A CN110840966A CN 110840966 A CN110840966 A CN 110840966A CN 201911298679 A CN201911298679 A CN 201911298679A CN 110840966 A CN110840966 A CN 110840966A
- Authority
- CN
- China
- Prior art keywords
- parts
- weight
- composition
- chewable tablet
- vitamin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 20
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 9
- 201000007930 alcohol dependence Diseases 0.000 title claims abstract description 9
- 239000007910 chewable tablet Substances 0.000 title claims description 20
- 229940068682 chewable tablet Drugs 0.000 title claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 41
- 150000001413 amino acids Chemical class 0.000 claims abstract description 17
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 15
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 15
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 14
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 13
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 13
- 235000017784 Mespilus germanica Nutrition 0.000 claims abstract description 12
- 244000182216 Mimusops elengi Species 0.000 claims abstract description 12
- 235000000560 Mimusops elengi Nutrition 0.000 claims abstract description 12
- 235000007837 Vangueria infausta Nutrition 0.000 claims abstract description 12
- 235000011477 liquorice Nutrition 0.000 claims abstract description 12
- 244000010000 Hovenia dulcis Species 0.000 claims abstract description 11
- 235000008584 Hovenia dulcis Nutrition 0.000 claims abstract description 11
- 244000111489 Gardenia augusta Species 0.000 claims abstract description 10
- 229930003231 vitamin Natural products 0.000 claims abstract description 7
- 235000013343 vitamin Nutrition 0.000 claims abstract description 7
- 239000011782 vitamin Substances 0.000 claims abstract description 7
- 229940088594 vitamin Drugs 0.000 claims abstract description 7
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 7
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 6
- 235000018958 Gardenia augusta Nutrition 0.000 claims abstract description 5
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 28
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 20
- 229940024606 amino acid Drugs 0.000 claims description 16
- 235000001014 amino acid Nutrition 0.000 claims description 16
- 235000019359 magnesium stearate Nutrition 0.000 claims description 14
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 12
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 12
- 229960003767 alanine Drugs 0.000 claims description 12
- 229960003136 leucine Drugs 0.000 claims description 12
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 12
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 10
- 239000008103 glucose Substances 0.000 claims description 10
- 238000002156 mixing Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 9
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N D-alpha-Ala Natural products CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 claims description 8
- QNAYBMKLOCPYGJ-UWTATZPHSA-N L-Alanine Natural products C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims description 8
- 235000019454 L-leucine Nutrition 0.000 claims description 8
- 239000004395 L-leucine Substances 0.000 claims description 8
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 6
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 6
- 229960002433 cysteine Drugs 0.000 claims description 6
- 235000010355 mannitol Nutrition 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- 239000000600 sorbitol Substances 0.000 claims description 6
- 235000010356 sorbitol Nutrition 0.000 claims description 6
- 229940013618 stevioside Drugs 0.000 claims description 6
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 claims description 6
- 235000019202 steviosides Nutrition 0.000 claims description 6
- 239000011726 vitamin B6 Substances 0.000 claims description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims description 6
- 229940011671 vitamin b6 Drugs 0.000 claims description 6
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 claims description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000007873 sieving Methods 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
- 235000018417 cysteine Nutrition 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 238000007605 air drying Methods 0.000 claims description 2
- 239000011230 binding agent Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 235000005772 leucine Nutrition 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 210000004185 liver Anatomy 0.000 abstract description 23
- 230000000694 effects Effects 0.000 abstract description 16
- 230000035622 drinking Effects 0.000 abstract description 14
- 230000004060 metabolic process Effects 0.000 abstract description 12
- 206010067125 Liver injury Diseases 0.000 abstract description 8
- 231100000753 hepatic injury Toxicity 0.000 abstract description 7
- 230000006378 damage Effects 0.000 abstract description 5
- 238000001727 in vivo Methods 0.000 abstract description 5
- 238000010521 absorption reaction Methods 0.000 abstract description 4
- 208000027418 Wounds and injury Diseases 0.000 abstract description 2
- 210000001156 gastric mucosa Anatomy 0.000 abstract description 2
- 208000014674 injury Diseases 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 9
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000001737 promoting effect Effects 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 230000001476 alcoholic effect Effects 0.000 description 6
- 210000005229 liver cell Anatomy 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000001154 acute effect Effects 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000013641 positive control Substances 0.000 description 5
- 239000003440 toxic substance Substances 0.000 description 5
- 206010019133 Hangover Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 230000004622 sleep time Effects 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 231100000167 toxic agent Toxicity 0.000 description 4
- 239000004201 L-cysteine Substances 0.000 description 3
- 235000013878 L-cysteine Nutrition 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 230000028527 righting reflex Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 210000000232 gallbladder Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 2
- 229960004949 glycyrrhizic acid Drugs 0.000 description 2
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 2
- 235000019410 glycyrrhizin Nutrition 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 239000002398 materia medica Substances 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000007779 soft material Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 1
- 208000005584 Alcoholic Intoxication Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- ZUKLFFYDSALIQW-MSUKCBDUSA-N Iridoid glycoside Chemical compound [H][C@]12CC[C@H](C(O)=O)[C@@]1([H])[C@H](OC1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O)OC=C2 ZUKLFFYDSALIQW-MSUKCBDUSA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- IKHGUXGNUITLKF-XPULMUKRSA-N acetaldehyde Chemical compound [14CH]([14CH3])=O IKHGUXGNUITLKF-XPULMUKRSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000001780 adrenocortical effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 108010081577 aldehyde dehydrogenase (NAD(P)+) Proteins 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000007767 bonding agent Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- OLOZVPHKXALCRI-UHFFFAOYSA-L calcium malate Chemical compound [Ca+2].[O-]C(=O)C(O)CC([O-])=O OLOZVPHKXALCRI-UHFFFAOYSA-L 0.000 description 1
- 229940016114 calcium malate Drugs 0.000 description 1
- 239000001362 calcium malate Substances 0.000 description 1
- 235000011038 calcium malates Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000021403 cultural food Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000002892 effect on hypertension Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- -1 flavonoid compounds Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 229930182489 iridoid glycoside Natural products 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 229940118019 malondialdehyde Drugs 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 230000036578 sleeping time Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 235000019156 vitamin B Nutrition 0.000 description 1
- 239000011720 vitamin B Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4415—Pyridoxine, i.e. Vitamin B6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/72—Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/81—Solanaceae (Potato family), e.g. tobacco, nightshade, tomato, belladonna, capsicum or jimsonweed
- A61K36/815—Lycium (desert-thorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明提供一种用于解酒的组合物，所述组合物按重量份包括：葛根50‑150份，枳椇子25‑75份，栀子5‑15份，枸杞5‑15份，甘草5‑15份，氨基酸40‑120份，维生素0.2‑1.0份。服用本品后可以在增加酒精在体内的快速代谢、减少酒精的有效吸收、保护酒精在肝脏代谢引起的肝损伤以及保护饮酒引起的胃粘膜伤害等方面有较好的作用，从而全面的消除因应酬饮酒带来的痛苦。
Description
技术领域
本发明涉及中药技术领域，具体地涉及一种用于解酒的组合物及包含其的咀嚼片。
背景技术
据了解，长期大量喝酒对人体健康容易造成影响，主要有以下身体危害：
1.长期大量喝酒的情况下，人们出现肝脏部位的病变概率非常高。因为酒精主要在人体肝脏进行代谢，如果经常大量喝酒，酒精物质超过了肝脏的代谢负担，此时人的肝细胞就会受到损伤，甚至引发严重的肝硬化，酒精肝，脂肪肝等。如果这些肝脏疾病没有及时治疗和改善，而且治疗过程中依然大量喝酒，还可能会诱发严重的肝癌。
2.长期大量喝酒的情况下，人的消化能力也会下降，容易在喝酒之后出现腹泻的情况。因为酒精物质在经过人体肠胃道的时候，会对肠胃道营黏膜造成刺激。如果本身患有某些肠胃道疾病，此时酒精物质会加重局部炎症的发展，甚至出现多种不良症状。
3.在长期大量喝酒的情况下，人的性能力也会受到影响，部分男性经常大量喝酒，短时间内发现自己有腰膝酸软，四肢乏力或者头晕耳鸣的症状，多半和饮酒有关。因为饮酒过量的情况下，对人的肾脏也会造成影响，就容易引发肾虚而导致男性的性功能开始下降。
但是酒文化是中华民族饮食文化的—个重要组成部分在中国，酒经常被当做一种工具；酒在中国人眼里更多的是当作一种交际的工具。所以在现实生活中许多人出现了饮酒问题，如何缓解饮酒给喝酒者身体带来的伤害具有重要的现实意义。为此，本发明提供一种对饮酒者身体进行保护的中药组合物。
发明内容
为了解决上述问题，本发明提供一种用于解酒的组合物，所述组合物按重量份包括：葛根50-150份，枳椇子25-75份，栀子5-15份，枸杞5-15份，甘草5-15份，氨基酸40-120份，维生素0.2-1.0份。
在一种实施方式中，所述氨基酸包括丙氨酸、亮氨酸和半胱氨酸，按重量份三者之间比例关系为5-15：4-8：0.5-1.5。
在一种实施方式中，所述氨基酸包括L-丙氨酸、L-亮氨酸和L-半胱氨酸，按重量份三者之间比例关系为10：6：1。
在一种实施方式中，所述维生素是维生素B6。
在一种实施方式中，所述组合物按重量份包括：葛根100份，枳椇子50 份，栀子10份，枸杞10份，甘草10份，氨基酸80份，维生素0.5份份。
在一种实施方式中，本发明提供一种包括上述组合物的咀嚼片。
在一种实施方式中，所述咀嚼片中还包括葡萄糖、D-甘露糖醇、山梨糖醇、甜菊糖苷和硬脂酸镁，按重量份五种组分之间比例关系为80-160：20-40： 20-40：1-2和1-2；葛根和葡萄糖按重量份比例为1:0.5-1.5。
在一种实施方式中，所述咀嚼片包括：500重量份葛根、250重量份枳椇子、50重量份栀子、50重量份枸杞、50重量份甘草、750重量份葡萄糖、 150重量份D-甘露糖醇、150重量份山梨糖醇、200重量份L-丙氨酸、175 重量份L-亮氨酸、25重量份L-半胱氨酸、5重量份硬脂酸镁、1重量份维生素B6和4重量份甜菊糖苷。
在一种实施方式中，所述咀嚼片包括：1500重量份葛根、750重量份枳椇子、50重量份栀子、50重量份枸杞、50重量份甘草、500重量份葡萄糖、 50重量份D-甘露糖醇、150重量份山梨糖醇、100重量份L-丙氨酸、100重量份L-亮氨酸、50重量份L-半胱氨酸、10重量份硬脂酸镁、1重量份维生素B6和8重量份甜菊糖苷。
在一种实施方式中，本发明提供一种制备上述咀嚼片的方法，其特征在于，所述方法包括以下步骤：步骤1：取处方中葛根、枳椇子、栀子、枸杞及甘草，加5-10倍重量的水煎煮1-3次，每次1-3小时，合并煎煮液，滤过，浓缩成稠膏，真空干燥，粉碎成细粉；和步骤2：加入处方中硬脂酸镁之外的其它组分混合均匀，用乙醇作粘合剂制成软材，过筛制成湿颗粒，鼓风干燥，控制水分≤5.0％，过筛，加入硬脂酸镁，混合均匀，压片。
在本发明的组合物中，君药葛根性甘、辛，凉。归脾、胃、肺经。具有解肌退热，生津止渴，透疹，升阳止泻，通经活络，解酒毒。《本草纲目》载：具清热、降火、排诸毒功效；《千金方》载：治酒醉不醒；《药性论》载： "治天行上气，呕逆，开胃下食，主解酒毒，止烦渴；治胃虚热渴，酒毒呕吐。"葛根能有效地抵抗由酒精引起的肝和睾丸组织脂质过氧化损害，葛根含有丰富的黄酮类化合物，它能有效的分解乙醛毒性，能阻止酒精对大脑抑制功能的减弱；能抑制肠胃对酒精的吸收，促进血液中酒精的代谢和排泄。同时葛根对高血压、高血脂、高血糖和心脑血管疾病也是疗效显著。
枳椇子性味甘、平，《本草再新》载其入心、脾二经。功用除烦渴，解酒毒，利小便。枳椇子富含葡萄糖和苹果酸钙，有较强的利尿作用，能促使酒精的分解和排出，明显降低酒精在血液中的浓度，并可以消除酒精在体内产生的自由基，阻止过氧化酯质的形成，从而减轻酒精对肝组织的损伤，避免酒精中毒导致各种代谢异常，诱发各种疾病。
枸杞子甘，平。归肝、肾经。具有滋补肝肾，益精明目之功效。枸杞中多糖成分及甜菜碱等物质能保护肝脏，抑制脂肪在肝脏中囤积，促进肝细胞的活化作用，修护受损的肝细胞，有效的保护酒精在肝脏代谢引起的肝损害。另外枸杞具有抗衰老、降三高、增强免疫力等功效。
栀子苦，寒。归心、肺、胃、三焦经。泻火除烦，清热利尿，凉血解毒，消肿止痛。栀子所含环烯醚萜甙等成分均有保肝利胆的作用，其能够促胆汁分泌，从而起到收缩胆囊、加快胆红素排泄的作用，有效成分还能够促进胰腺分泌，从而增加正常的肝血流量，以此达到保肝利胆的作用。从而达有效的避免饮酒引起的急性酒精性肝损伤。
甘草甘，平。入脾、胃、肺经。补脾益气，淸热解毒，祛痰止咳，缓急止痛，调和诸药。甘草制剂能促进胃部粘液形成和分泌，护胃抗炎，利咽解毒。甘草有效成份甘草甜素对毒物有吸附作用，水解产物葡萄糖醛酸能与毒物结合，甘草甜素有肾上腺皮质激素样作用，增强肝脏的解毒能力等方面因素综合作用的结果。
辅料葡萄糖具有为人体提供能量和利尿、促进人体新陈代谢的作用，能够加快肝细胞对酒精的分解和肾脏的排泄，缓解酒精的吸收。
方中L-丙氨酸、L-亮氨酸、L-半胱氨酸为氨基酸成分，氨基酸是组成人体的重要物质，每个细胞的重要组成部分都需要氨基酸参与，没有氨基酸就没有生命。L-丙氨酸、L-亮氨酸、L-半胱氨酸极易被人体吸收和利用，提高血液中丙氨酸和亮氨酸的浓度，能够产生稳定的分解乙醇的辅脱氢酶，增强肝脏乙醇脱氢酶和乙醛脱氢酶的活性，促进体内乙醇的分解和代谢，从而降低血液中乙醇的浓度，达到降低醉酒程度和醒酒的作用。部分氨基酸能促进肝中肝药酶的活力，加速酒精在体内的转化、分解，而且能修復受损的肝细胞，半胱氨酸就是其中的主要类型。另外，一些氨基酸能促进酒精代谢，如丙氨酸等；氨基酸成份亮氨酸可以加速酒精分解，促进酒精代谢，帮你減轻肝的负荷，也使您能承受或增加酒量。
维生素B群尤其是VB6对肝脏有一定的保护作用。VB6为多种酶的辅基，参于氨基酸和脂肪的代谢，并促进酒精的代谢。
服用本品后可以在增加酒精在体内的快速代谢、减少酒精的有效吸收、保护酒精在肝脏代谢引起的肝损伤以及保护饮酒引起的胃粘膜伤害等方面有较好的作用，从而全面的消除因应酬饮酒带来的痛苦。
具体实施方式
为了使本领域技术领域人员更好地理解本申请中的技术方案，下面将结合下面结合实施例对本发明作进一步说明，显然，所描述的实施例仅仅是本申请一部分实施例，而不是全部的实施例。基于本申请中的实施例，本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其它实施例，都应当属于本申请保护的范围。下面结合实施例对本发明作进一步描述。
实施例一本发明解酒的咀嚼片配方1
配方1组成：
配方1咀嚼片制备工艺如下：
取处方中葛根、枳椇子、栀子、枸杞及甘草，加10倍量的水煎煮2 次，每次3小时，合并煎煮液，滤过，浓缩成稠膏，真空干燥，粉碎成细粉，加入处方中其他辅料(硬脂酸镁除外)混合均匀，用80％乙醇作粘合剂制成软材，经18目筛制成湿颗粒，置60～70℃鼓风干燥，控制水分≤5.0％，经16目筛整粒，加入硬脂酸镁，混合均匀，压片，装瓶，即得。
实施例二本发明解酒的咀嚼片配方2
配方2咀嚼片制备工艺如下：
取处方中葛根、枳椇子、栀子、枸杞及甘草，加8倍量的水煎煮2 次，每次2小时，合并煎煮液，滤过，浓缩成稠膏，真空干燥，粉碎成细粉，加入处方中其他辅料(硬脂酸镁除外)混合均匀，用50％乙醇作粘合剂制成软材，经18目筛制成湿颗粒，置60～70℃鼓风干燥，控制水分≤5.0％，经16目筛整粒，加入硬脂酸镁，混合均匀，压片，装瓶，即得。
实施例三动物毒性试验
健康成年小鼠40只，雌雄各半，体重10-20g/只，分成二组。将本发明的配方1和配方2分别加30倍水稀释成悬浮液，在小鼠禁食(不禁水)20 小时后，一天两次灌胃，每次5ml，10天后，小鼠未见死亡，表明本发明的咀嚼片无毒。
实施例四小鼠解酒实验
取昆明种小鼠160只，雌雄各半，随机分为4组(模型组、阳性对照组、配方1组、配方2组)，每组10只，测试前禁食15小时，试验时小鼠以0.2mL/10g给予白酒灌胃，灌酒30分钟后以0.5mL/10g灌胃本发明的中药组合物悬浮物，阳性对照组灌胃海王金樽(1.5g/kg)。以翻正反射消失为睡眠指标，计算耐受时间(从白酒灌胃到翻正反射消失的时间)及醉睡时间(从翻正反射消失到恢复的时间)。
| 组别 | 耐受时间 | 睡眠时间 |
| 配方1组 | 50±2.5分钟 | 70±4.3分钟 |
| 配方2组 | 63±3.8分钟 | 50±2.6分钟 |
| 模型组 | 20±1.5分钟 | 110±6.5分钟 |
| 阳性对照组 | 68±5.2分钟 | 65±5.6分钟 |
实验结果表明：(1)模型组小鼠给予白酒灌胃后耐受时间较短，睡眠时间较长；(2)本发明的配方1和配方2能延长醉酒小鼠的耐受时间，缩短醉酒小鼠的睡眠时间，与模型组相比，有显著性差异(P<0.05)；(3)配方 2组和配方1组相比，小鼠的睡眠时间更短，耐受时间更长，差异具有显著性(P>0.05)。
实验例五检测本发明配方1和配方2对急性酒精性肝损伤的有效性
体重200g左右的雄性大鼠分为4组：本发明配方1组、配方2组、白对照组(生理盐水)和阳性对照组(海王金樽)。根据文献公认的急性酒精性肝损伤模型造模，方法：大鼠连续灌胃54度白酒(20.0ml/kg)5天以造成大鼠急性酒精性肝损伤模型。灌胃白酒1h后灌胃给药，每天1次，连续5天。末次给药后，处死大鼠，快速取出肝脏，其中一部分用作冷冻切片，进行病理组织学检查；另一部分用于制成肝匀浆分别测定肝组织中丙二醛MDA、还原谷胱甘肽GSH和乙醇脱氢酶ADH的含量。
通过综合上述评价指标，评价本发明配方1组、配方2组对大鼠急性酒精性肝损伤保护效果的影响，配方1组和配方2组与阳性对照组效果类似，不存在显著差异(P>0.05)，而与对照组相比有显著差异(P>0.05)。
应该理解到披露的本发明不仅仅限于描述的特定的方法、方案和物质，因为这些均可变化。还应理解这里所用的术语仅仅是为了描述特定的实施方式方案的目的，而不是意欲限制本发明的范围，本发明的范围仅受限于所附的权利要求。
本领域的技术人员还将认识到，或者能够确认使用不超过常规实验，在本文中所述的本发明的具体的实施方案的许多等价物。这些等价物也包含在所附的权利要求中。
Claims (10)
1.一种用于解酒的组合物，其特征在于，所述组合物按重量份包括：葛根50-150份，枳椇子25-75份，栀子5-15份，枸杞5-15份，甘草5-15份，氨基酸40-120份，维生素0.2-1.0份。
2.根据权利要求1所述的组合物，其特征在于，所述氨基酸包括丙氨酸、亮氨酸和半胱氨酸，按重量份三者之间比例关系为5-15：4-8：0.5-1.5。
3.根据权利要求2所述的组合物，其特征在于，所述氨基酸包括L-丙氨酸、L-亮氨酸和L-半胱氨酸，按重量份三者之间比例关系为10：6：1。
4.根据权利要求1所述的组合物，其特征在于，所述维生素是维生素B6。
5.根据权利要求1所述的组合物，其特征在于，所述组合物按重量份包括：葛根100份，枳椇子50份，栀子10份，枸杞10份，甘草10份，氨基酸80份，维生素0.5份。
6.一种咀嚼片，其特征在于，所述咀嚼片包括根据权利要求1-5任一所述的组合物。
7.根据权利要求6所述的咀嚼片，其特征在于，所述咀嚼片中还包括葡萄糖、D-甘露糖醇、山梨糖醇、甜菊糖苷和硬脂酸镁，按重量份五种组分之间比例关系为80-160：20-40：20-40：1-2和1-2；葛根和葡萄糖按重量份比例为1:0.5-1.5。
8.根据权利要求7所述的咀嚼片，其特征在于，所述咀嚼片包括：500重量份葛根、250重量份枳椇子、50重量份栀子、50重量份枸杞、50重量份甘草、750重量份葡萄糖、150重量份D-甘露糖醇、150重量份山梨糖醇、200重量份L-丙氨酸、175重量份L-亮氨酸、25重量份L-半胱氨酸、5重量份硬脂酸镁、1重量份维生素B6和4重量份甜菊糖苷。
9.根据权利要求7所述的咀嚼片，其特征在于，所述咀嚼片包括：1500重量份葛根、750重量份枳椇子、50重量份栀子、50重量份枸杞、50重量份甘草、500重量份葡萄糖、50重量份D-甘露糖醇、150重量份山梨糖醇、100重量份L-丙氨酸、100重量份L-亮氨酸、50重量份L-半胱氨酸、10重量份硬脂酸镁、1重量份维生素B6和8重量份甜菊糖苷。
10.一种制备权利要求6-9任一所述的咀嚼片的方法，其特征在于，所述方法包括以下步骤：
步骤1：取处方中葛根、枳椇子、栀子、枸杞及甘草，加5-10倍重量的水煎煮1-3次，每次1-3小时，合并煎煮液，滤过，浓缩成稠膏，真空干燥，粉碎成细粉；
步骤2：加入处方中硬脂酸镁之外的其它组分混合均匀，用乙醇作粘合剂制成软材，过筛制成湿颗粒，鼓风干燥，控制水分≤5.0％，过筛，加入硬脂酸镁，混合均匀，压片。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911298679.6A CN110840966A (zh) | 2019-12-17 | 2019-12-17 | 一种用于解酒的组合物及包含其的咀嚼片 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911298679.6A CN110840966A (zh) | 2019-12-17 | 2019-12-17 | 一种用于解酒的组合物及包含其的咀嚼片 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110840966A true CN110840966A (zh) | 2020-02-28 |
Family
ID=69609442
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201911298679.6A Pending CN110840966A (zh) | 2019-12-17 | 2019-12-17 | 一种用于解酒的组合物及包含其的咀嚼片 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110840966A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111743003A (zh) * | 2020-07-02 | 2020-10-09 | 唐奇 | 一种具有解酒和保护消化道功能的组合物及其制备方法 |
| CN112168868A (zh) * | 2020-10-12 | 2021-01-05 | 陕西凤丹正元生物科技有限公司 | 一种牡丹花瓣微粉组合物及其在制备防治肝损伤的功能食品中的应用 |
| CN113142575A (zh) * | 2021-05-26 | 2021-07-23 | 宁波大榭开发区令泽食品厂 | 枳椇子嚼片 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101731630A (zh) * | 2010-01-22 | 2010-06-16 | 完美（中国）日用品有限公司 | 一种具有解酒、护肝功效的保健食品 |
| CN101757194A (zh) * | 2008-12-25 | 2010-06-30 | 沃德（天津）营养保健品有限公司 | 一种解酒产品及其制备方法 |
| CN103479793A (zh) * | 2013-09-24 | 2014-01-01 | 青海阿如拉藏医药研究开发有限公司 | 一种解酒保肝的组合物及其制备方法 |
| CN104784295A (zh) * | 2015-04-27 | 2015-07-22 | 无限极（中国）有限公司 | 一种解酒护肝中药组合物及其制备方法 |
| CN105362384A (zh) * | 2015-11-24 | 2016-03-02 | 中国人民解放军第二军医大学 | 一种解酒醒酒的中药组合物及其应用 |
| CN110354178A (zh) * | 2019-06-29 | 2019-10-22 | 吉林正昇康生物工程有限公司 | 一种具有解酒护胃保肝作用的组合物 |
-
2019
- 2019-12-17 CN CN201911298679.6A patent/CN110840966A/zh active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101757194A (zh) * | 2008-12-25 | 2010-06-30 | 沃德（天津）营养保健品有限公司 | 一种解酒产品及其制备方法 |
| CN101731630A (zh) * | 2010-01-22 | 2010-06-16 | 完美（中国）日用品有限公司 | 一种具有解酒、护肝功效的保健食品 |
| CN103479793A (zh) * | 2013-09-24 | 2014-01-01 | 青海阿如拉藏医药研究开发有限公司 | 一种解酒保肝的组合物及其制备方法 |
| CN104784295A (zh) * | 2015-04-27 | 2015-07-22 | 无限极（中国）有限公司 | 一种解酒护肝中药组合物及其制备方法 |
| CN105362384A (zh) * | 2015-11-24 | 2016-03-02 | 中国人民解放军第二军医大学 | 一种解酒醒酒的中药组合物及其应用 |
| CN110354178A (zh) * | 2019-06-29 | 2019-10-22 | 吉林正昇康生物工程有限公司 | 一种具有解酒护胃保肝作用的组合物 |
Non-Patent Citations (1)
| Title |
|---|
| 总站负责人：耿明波VIP：29021968: "完美氨基酸片", 《HTTPS://AIKO.WEBNODE.COM/NEWS/%E5%AE%8C%E7%BE%8E%E6%B0%A8%E5%9F%BA%E9%85%B8%E7%89%87/》 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111743003A (zh) * | 2020-07-02 | 2020-10-09 | 唐奇 | 一种具有解酒和保护消化道功能的组合物及其制备方法 |
| CN112168868A (zh) * | 2020-10-12 | 2021-01-05 | 陕西凤丹正元生物科技有限公司 | 一种牡丹花瓣微粉组合物及其在制备防治肝损伤的功能食品中的应用 |
| CN113142575A (zh) * | 2021-05-26 | 2021-07-23 | 宁波大榭开发区令泽食品厂 | 枳椇子嚼片 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106975069B (zh) | 一种保肝护肝组合物及其制备方法 | |
| CN110840966A (zh) | 一种用于解酒的组合物及包含其的咀嚼片 | |
| WO2016127463A1 (zh) | 一种保肝排毒降脂降糖药物及其应用 | |
| CN109170476A (zh) | 含有菊苣的保健食品 | |
| CN111870627A (zh) | 一种解酒制剂及其制备方法和用途 | |
| KR20100077781A (ko) | 발기부전에 효과적인 기능성 분말의 제조 방법, 이에 의한 기능성 분말을 포함하는 기능성 보조식품 | |
| CN111529579A (zh) | 一种醒酒、治疗酒精肝的中药组合物 | |
| CN107890528B (zh) | 一种治疗高尿酸血症的中药组合物及其制备方法 | |
| CN111135235A (zh) | 一种预防和缓解急性酒精中毒或醉酒的组合物 | |
| CN114642236A (zh) | 一种可以辅助降血压的小球藻纳豆压片糖果 | |
| CN114767826A (zh) | 一种醒酒护肝组合物、具有醒酒护肝功效的饮料及其制备方法 | |
| CN114404517A (zh) | 一种用于痛风和降低尿酸的组合物及其用途与制备方法 | |
| CN101234139B (zh) | 一种治疗感冒的中成药及其制备方法 | |
| CN114569686A (zh) | 一种解酒组合物、具有解酒功效的片剂及其制备方法 | |
| CN115089661A (zh) | 辅助调节内分泌代谢并抗癌防癌的人参组合物的应用 | |
| CN104383232B (zh) | 清热解毒苦丁茶含片及其生产方法 | |
| CN113577236A (zh) | 一种用于保肝护胃醒酒的中药组合物、制剂及其制备方法 | |
| CN112755168A (zh) | 一种治疗幽门螺旋杆菌引起的慢性胃炎的中药制剂及其制备方法和应用 | |
| CN114668830B (zh) | 一种解酒护肝组合物及其制备方法 | |
| CN115006460B (zh) | 一种解酒护肝中药组合物及其制备方法和应用 | |
| CN113893276B (zh) | 改善睡眠的组合物及其制备方法和应用 | |
| CN103800789A (zh) | 一种健脾补肾的中药组合物及其制备方法 | |
| CN105920070A (zh) | 治疗白内障的中药组合物及其制备方法 | |
| CN104189609B (zh) | 一种兽用解热中药复方制剂 | |
| CN106166251A (zh) | 一种用于治疗哮喘的中药制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200228 |
|
| RJ01 | Rejection of invention patent application after publication |